drugset / Trial / NCT00094328

Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]

NCT00094328

Phase 2 Completed 14 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to investigate whether bicalutamide given in combination with anastrozole once daily for 12 months is effective in treating testotoxicosis in boys. Testotoxicosis is a condition that causes early puberty in boys including growth in height, and development of muscles and sexual organs .

Timeline

Start
2004-11-22
Primary completion
2008-05-22
Completion
2017-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified Oral
Subject Bicalutamide Other / unclassified Oral

Indications